News
Mylan Receives Approval for Nabumetone Tablets
July 14, 2010 1:33 pm | by Bio-Medicine.Org | CommentsPITTSBURGH , July 14 /- Mylan Inc. (Nasdaq: MYL ) today announced that its subsidiary Matrix Laboratories Limited has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Nabumetone Tablets USP, 500 mg and 750 mg. The...
Drug detection firm Psychemedics signs deal with UK firm
July 14, 2010 12:32 pm | by Mass High Tech: The Journal of New England Technology | CommentsActon-based Psychemedics Corp., a substance abuse screening firm, has signed a deal with U.K.-based LGC Ltd., granting the British analytical and diagnostic services firm sales and marketing responsibilities in the U.K. and Europe for Psychemedics' hair analysis drug test.
Does the existing standard of care supply energy sources to brain tumor cells?
July 14, 2010 11:34 am | by EurekAlert | Comments(Boston College) Examining a decade's worth of research, Boston College biochemists write in Lancet Oncology that the medical standard of care for the most common form of brain cancer may actually feed tumor cells the energy sources they need to survive or recur.
Children's National Medical Center receives first NIH CTSA given to a children's hospital
July 14, 2010 11:34 am | by EurekAlert | Comments(Children's National Medical Center) Children's National Medical Center, in partnership with The George Washington University Medical Center, has received a prestigious Clinical and Translational Science Award from the National Center for Research Resources of the National...
EnVivo Pharmaceuticals Announces Significant Results from GSM Transgenic Mouse Model for Alzheimer's Disease
July 14, 2010 10:39 am | by Bio-Medicine.Org | CommentsHONOLULU , July 14 /- EnVivo Pharmaceuticals today announced at the Alzheimer's Association 2010 International Conference on Alzheimer's Disease (ICAD) results from its proprietary gamma-secretase modulator (GSM) pre-clinical study. In a transgenic mouse model, EnVivo's EVP-0015962...
Viveve-Sponsored Research Accepted for Presentation at Two Prestigious International Conferences
July 14, 2010 9:46 am | by Bio-Medicine.Org | CommentsPALO ALTO, Calif. , July 14 /- Viveve, Inc., a women's sexual health company that has developed a medical device and procedure to treat vaginal laxity, recently received notification that its sponsored abstracts were accepted for the 2010 International Meetings for the International...
Cubist drug passes Phase 2 safety test
July 14, 2010 9:45 am | by Mass High Tech: The Journal of New England Technology | CommentsCubist Pharmaceuticals Inc. has met its safety objectives in a Phase 2 study of Cubicin, its treatment intended for prosthetic joint infections.
Dr. Nie Wentao's New Method of Diabetic Nutrition Interventions
July 14, 2010 9:45 am | by Bio-Medicine.Org | CommentsYINCHUAN, China , July 14 /PRNewswire-Asia/ -- Recently, Xinhua Website reported about Dr. Nie Wentao's nutrition intervention technology for type 1 diabetes mellitus. Dr. Nie Wentao's diabetic treatment technology is becoming a mainstream technology for diabetes treatment, so it aroused...
Helix Bioscience Appointed DNA Drug Sensitivity Testing Distributor for Genelex Corporation
July 14, 2010 9:45 am | by Bio-Medicine.Org | CommentsSEATTLE and TULSA, Okla. , July 14 /- Genelex and Helix have announced a personalized prescribing strategic alliance to increase the availability of important new DNA Drug Sensitivity Tests such as Plavitestâ„¢ and Tamoxitestâ„¢. These tests and the GeneMedRx medication management...
Renhuang Showcases its All Natural Products at 45th China National New and Special Drugs Fair
July 14, 2010 9:43 am | by Bio-Medicine.Org | CommentsHARBIN, China , July 14 /PRNewswire-Asia-FirstCall/ -- Renhuang Pharmaceuticals, Inc. (NYSE Amex: CBP ) ("Renhuang" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ("TCM"), today announced that...
MarketsandMarkets: Patient Monitoring Devices Markets in Brazil, Russia, India and China Worth $2,992 Million by 2015
July 14, 2010 9:43 am | by Bio-Medicine.Org | CommentsDALLAS , July 14, 2010 /- According to a new market research report, 'Patient Monitoring Devices - Emerging Markets BRIC ( Brazil , Russia , India and China ) 2010-2015, published by MarketsandMarkets ( http://www.marketsandmarkets.com ), the BRIC patient monitoring market is expected to...
Silence Therapeutics and AstraZeneca Extend siRNA Development Collaboration
July 14, 2010 9:43 am | by Bio-Medicine.Org | CommentsLONDON , July 14 /- Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company") is pleased to announce a one-year extension of its ongoing research and development collaboration with AstraZeneca. Under the terms of the agreement, which has progressed well since being signed in...
Sector Snap: SEC inquiry sacks home health stocks
July 14, 2010 8:45 am | by The Associated Press | CommentsShares of home health providers sank Wednesday as an investigation into the industry's Medicare reimbursement practices expanded.After the markets closed on Tuesday, LHC Group Inc. and Gentiva Health Services Inc. said they are being investigated by the Securities and Exchange Commission. LHC...
Half of swine flu deaths were in previously healthy people, research finds
July 14, 2010 6:48 am | by EurekAlert | Comments(University of Liverpool) Over half of UK swine flu hospital admissions and inpatient deaths occurred in people with no underlying health problems or obvious risk factors, research at the University of Liverpool has found.
Researcher targets gene regulators on link between arsenic, cancer
July 14, 2010 6:48 am | by EurekAlert | Comments(Michigan State University) To determine how arsenic increases the risk of lung cancer and to identify potential treatments, a Michigan State University researcher will use $1.7 million in federal funding during the next five years to examine why certain genes disrupt cells,...
